In the last decades new pharmacodynamic properties of -adrenoceptors have been discovered that could greatly impact in the use of -adrenergic agents in the clinical practice. Concepts such as multiple binding sites, constitutive activity, polymorphism and intracellular signaling of -adrenoceptors may contribute in the discovery of more efficacious pharmacological agents for treatment of heart failure and asthma. -Adrenoceptors show a relative high constitutive activity in both cardiac and pulmonar tissues. Most -blockers exert an inverse agonist action that could contribute to their beneficial effects in the treatment of heart failure. Recently, the existence of multiple affinity sites has been described for 1 adrenoceptor. It was proposed that -blockers that show agonist properties at the 1L -adrenoceptors binding site may exert neutral or harmful effects when used for treatment of heart failure. Considering the cardiac effect of 1L -adrenoceptors, activation of the low-affinity state of 1 -adrenoceptor could be deleterous in cardiovascular pharmacology. The ability of 2 -adrenoceptor to couple to Gs or Gi-protein gives the possibility that different agonists can activate different signaling cascades. Full 2 -adrenoceptor agonists would be highly useful for improvement bronchodilatation in the acute treatment of asthma. Polymorphic variants of -adrenoceptors have profound impact in the understanding of normal physiology and pathophysiology. Genotypic characterization of patients could improve selection of patients during -adrenergic pharmacotherapies.
INTRODUCTION -Adrenoceptors Signaling Transduction
adrenoceptors ( ARs) belong to the G protein coupled receptors (GPCR) super family, which is characterized by a conserved 7-transmembrane domain motif with an extracellular N terminus and an intracellular C terminus [1, 2] . It is well known that linear signaling cascade of GPCR presents the ligand-receptor-G protein-second messenger-biological effect sequence [3] .
Classical description of ARs stimulation consists of a signaling cascade involving a G stimulatory protein (Gs) and adenylyl cyclase (AC) activation, followed by an increase in cyclic adenine monophosphate (cAMP) and protein kinase A (PKA) activity and PKA-dependent protein phosphorylation [1, 4] .
Localization of G-protein-coupled receptors within membrane microdomains is associated with differential signaling pathways activation. Caveolar microdomains have been proposed to be sites that concentrate GPCRs, hetero-In the heart, 75% of ARs are 1 subtype, which appear to be distributed throughout the sarcolemma. Acute 1 -AR stimulation regulates cardiac Ca 2+ current (ICa) by a PKAdependent mechanism [10] [11] [12] . On the other hand, 1 AR stimulation also activates PKA-independent pathways, such as the calmodulin dependent protein kinase II (CaMKII). It is important to mention that it has been proposed that persistent cardiac 1 AR stimulation changes the receptor signaling pathway from PKA to Ca 2+ /CaMKII predominance, leading to myocyte apoptosis and maladaptive cardiac remodeling [4, 7, 13] . Wang et al. [14] showed that cAMP/PKA signaling is biphasic with a prominent early peak, whereas the CaMKII signaling is slow but persistent. As a result, the effects of sustained 1 AR stimulation (e.g: inotropy, cell growth, and cell death) are due primarily to CaMKII.
Phosphorylation and desentization of 1 AR is considered predominantly as a protective mechanism that decreases Gs-mediated signal transduction [15] . GPCR phosphorylation by G-protein-coupled receptor kinases (GRKs), leads to recruitment of -arrestin, which then interdicts further coupling to GCPR, targeting the receptor for internalization [3] . Interestingly, GRK phosphorylation of 1 AR does not only reduces Gs/PKA-mediated signal transduction, but also induces an antiapoptotic signaling by means of transactivation of the epidermal growth factor receptor (EGFR) through a -arrestin-dependent pathway [16] .
-Adrenoceptor Signaling Pathway
2 ARs are widely and ubiquitously expressed ( Table 1) , and their activation on smooth muscle causes relaxation. 2 AR is linked by Gs protein to AC, which increases cAMP, thus activating PKA, which affects calcium levels and reduces the efficiency of myosin light-chain kinase, causing relaxation [17, 18] . The increase in cAMP also results in the inhibition of calcium ions release from intracellular stores, reduction of membrane Ca 2+ entry, and sequestration of intracellular Ca 2+ . This receptor also opens the K + channels by a cAMP/PKA mechanism [18] . The relaxant effect of 2 AR stimulation might be mediated, at least in part, by a direct interaction of Gs with K + channels through a cAMPindependent mechanism [17] .
Although most of the 2 AR signaling transduction seems to be mediated by Gs proteins and the cAMP and PKA pathways, 2 AR can also couple to G inhibitory protein (Gi) , that inhibits AC [7, 17] . This mechanism might serve to uncouple the 2 AR from Gs protein. Activation of Gi pathway requires that the receptor be phosphorylated by PKA and is mediated by subunits of Gi protein acting as an assembly scaffold for many intracellular proteins, including non receptor tyrosine kinase cSrc, Raf and RAS, culminating in the MAPK stimulation [7, 17] .
2 AR activates both Gs and Gi pathways in several smooth muscles and the mammalian heart, including humans [1, 4, 8, 17, 19] . In rat ventricular cardiomyocytes, 2 AR also couple to Gs-and Gi-protein. The receptor G-protein coupling is switched from Gs to Gi during persistent receptor stimulation, but PKA-mediated receptor phosphorylation is required for 2 AR-Gi-coupling in rodent cardiomyocites [7, 19, 20] . This Gi pathway activates PI3K, which inhibits the Gs pathways mediated target protein phosphorylation and positive inotropic and lusitropic effects [7, 10, 11, 21] . Switching of 2 AR from Gs to Gi might contribute to receptor desensitization in terms of inotropic response.
Several lines of evidence suggest that the Gi signaling pathway exerts a cardioprotective effect against cardiomyocytes apopotosis and attenuates the Gs-mediated inotropic response. 2 AR blockade enhances 1 -adrenoceptor-induced apoptosis in cultured adult rat myocytes in a PTX-sensitive manner, suggesting that the 2 AR protective effect is Gi-dependent [22] . Therefore, cardioprotective effect of long term 2 AR signaling is mediated by the Gi pathway involving Gi , PI3K and Akt [23, 24] .
Nevertheless, it has been observed that enhanced 2 AR -Gi signaling blunts the Gs-mediated stimulation of L-type Ca 2+ current (I Ca,L ) and contractile support in a canine heart failure model, thus contributing to the contractile defect of the failing heart [8, 25,] . Conversely, Molenaar et al. [26] suggested that sustained relaxant and biochemical effects of adrenaline through 2 AR and of noradrenaline through 1 AR in heart failure are inconsistent with a role of coupling of 2 AR with Gi -protein in human atrial myocardium.
It is well known that vascular 2 AR mediates vasodilation through an action on vascular smooth muscle cells via cAMP pathway. However, 2 AR dependent vasorelaxation is mediated at, least in part, by endothelial nitric oxide (NO) dependent processes [27] . Iaccarino et al. [28] demonstrated that the 2 ARs are expressed on endothelial cells and their stimulation causes endothelial nitric oxide synthase (eNOS) activation. The eNOS activity is regulated by both a calcium/calmodulin dependent fashion [29] and phosphorylation of Ser 1177 in eNOS sequence [30, 31] . Endothelial 2 AR regulates eNOS activity and consequently vascular tone, through means of PKB/Akt [32] .
Insulin-independent stimulation of glucose uptake (GU) in response to adrenoceptor stimulation have been reported in the rat skeletal muscle cell line L6, where GU is increased by activation of Gs coupled 2 AR [33, 34] . In chicken astrocytes, 2 AR activation of GU involves stimulation of AC to produce cAMP, which by a mechanism not clarified causes activation of PI3K and PKC [35] . It is interesting to point out that Kanda and Watanabe suggested that adrenaline induced GU in vascular smooth muscle is mediated by AR, Gs, AC, Rap1 and p38MAPK pathway [36] .
Phosphodiesterase (PDE) isoforms regulate 2 AR signaling. The PDE4D isoenzyme regulates signaling by the 2 AR but has no detectable effect on 1 AR signaling [37] . The PDE4D5 isoform preferentially interacts with the signaling scaffold protein -arrestin and is thereby recruited to the 2 AR upon agonist stimulation [38, 39] . Delivery of an ac-tive PDE to the site of cAMP synthesis at the plasma membrane specifically attenuates the activity of a PKA pool [39] . The role of this anchored PKA is to phosphorylate the 2 AR, allowing it to switch its coupling with Gi and thereby activating extracellular-signal-regulated kinase (ERK) [39] . Thus, -arrestin-recruited PDE4 provides the mechanism of desensitizing the agonist-dependent coupling of 2 AR with Gi and its consequential activation of ERK [38, 39] .
3 AR are preferentially localized in the adipose tissue and heart ( Table 1) . In adipose tissue, stimulation of 3 AR increases cAMP production via classical activation of Gs, inducing lypolisis [40, 41] . In the heart, 3 AR is coupled to Gi proteins. Pretreatment with pertussis toxin of human ventricular tissues, canine and rat cardiomyocytes abolishes the negative inotropic effect induced by 3 AR stimulation [42, 43] . Moreover, 3 AR can couple interchangeably to both Gs and Gi without requiring receptor phosphorylation [43, 44] .
Stimulation of cardiac 3 AR leads to a decrease in contractility via NO release [13, 45, 46] . In human heart, the activation of Gi proteins enhances the NO pathway, probably implicating eNOS [13, 47] . Different molecular mechanisms of eNOS activation have been uncovered to occur as a consequence of 3 AR stimulation. It has been demonstrated that eNOS activity in human nonfailing myocardium can be modulated by receptor-induced P13K/Akt/PKB-dependent phosphorylation of eNOS [48] . The vascular 3 AR stimulation induces vasodilation but the signaling pathway shows apparent variability according to the vascular tissue studied [45] . In the rat thoracic aorta, endothelial 3 AR acts through activation of a NO synthase pathway and a subsequent increase in intracellular cGMP levels [45] , involving several K + channels [49] . 3 AR signaling also includes the MAP kinase (ERK1/2) pathway. It was found that 3 AR stimulation causes phosphorylation and activation of ERK1/2 in brown adipocytes [50] [51] [52] . Constitutive 3 AR coupling to Gi proteins serves both to restrain Gs-mediated activation of AC and to initiate the ERK1/2 MAP kinase cascade [44] . 3 AR activates ERK by a mechanism that depends on a series of proline-rich motifs in its third intracellular domain and carboxyl terminus that are conserved among the mammalian homologues [53] . It is through these regions that the Src kinase is recruited to the 3 AR. This interaction triggers Src catalytic activity, which together are necessary steps in ERK activation [53] . One of the functional consequences of the ERK cascade in adipocytes is lipolysis wherein ERK functions together with PKA to produce maximal lipolytic capacity [54] . Recently, it was reported that a vimentin filament assembly is necessary for 3 AR-mediated ERK activation and lipolysis [55] . This interaction places vimentin as a structural link between the 3 AR-Src complex and ERK activation. On the other hand, it has been reported that -adrenergic lipolysis involves NO production downstream of 3 AR/cAMP pathway [56] .
cAMP apparently contributes to AR-mediated bladder relaxation only in a minor way and large conductance Ca 2+ -activated K + channels (BKCa) may play a greater role in ARs-mediated bladder relaxation [57] .
3 AR can also activate glucose transport through three pathways: 1) Gs activation; 2) interaction with other G proteins, e.g. Gi (the release of G or Gq); or 3) a direct receptor interaction with an atypical signaling molecule [58] .
The Constitutive Activity and Inverse Agonism
Nowadays it is well known that GPCR can be spontaneously active in the absence of an agonist [59, 60] . Receptors constitutive activity has been described using the two-state model that implies GPCR to be in equilibrium between an active and inactive conformation. In the inactive conformation, receptors are thought to be functionally uncoupled from G protein, while active receptor conformation leads to coupling and activation of G proteins. Isomerization of the inactive towards the active conformation may occur by agonist activation and spontaneously in the absence of an agonist [61, 62] .
Taking into account basal receptor activity, a new class of ligands, called as inverse agonists, has been described as stabilizing the inactive conformation of receptors [63] . The multistate equilibrium model of receptors classified ligands with regard to their differential affinity to the active/inactive receptor conformation [64] . Traditional agonists bind with a greater affinity to the active conformation of the receptor and help in stabilizing this conformation. Neutral antagonists have identical affinity for both receptor conformations and therefore do not stabilize preferentially either the active or the inactive conformation. Conversely, inverse agonists show higher affinity for the inactive state compared with the active conformation, reducing constitutive activity [64] . Using 2 AR as a model, Bhattcharya et al. [65] showed that the receptor conformational state depends on the structure and efficacy of the ligand for a given signaling pathway.
To date, controversies exist regarding the therapeutic relevance of GPCR constitutive activity and the use of inverse agonists in drug therapy [66, 67] . Although inverse agonism has been described for a large number of compounds, most studies were made in non-physiological systems [64] . Commonly, GPCRs have a very low basal activity in physiological tissues. Therefore, techniques such as constitutively active mutants (CAM) and receptor overexpression have been used to increase basal receptor activity, allowing the screening of compounds with negative activity [64] . Conversely, only few studies have evaluated inverse agonistic properties of drugs in native systems.
ARs have been found to have constitutive activity not only in enginered systems but also in native tissues, including the heart and the lungs [64, 68] . Samama et al. [69] designed a CAM of 2 AR by replacing the carboxyl-terminal portion of the third intracellular loop of the receptor with the homologous region of 1 AR. In COS-7 and chinese hamster ovary (CHO) cells expressing CAM 2 AR, the authors found that ICI-118551 and betaxolol inhibited basal activity of 2 AR acting as inverse agonist [69] . In another report, Chidiac et al. [62] studied the effect of several 2 AR antago-nists on basal activity in chinese hamster fibroblasts overexpressing wild-type 2 AR. The rank order for the ability of different inverse agonists to inhibit constitutive activity was timolol > propranolol > alprenolol > pindolol > labetalol > dichloroisoproterenol.
Most importantly, constitutive activity of 2 AR was also described in physiological conditions. Mewes et al. [70] have performed an electrophysiological study showing that ARs are constitutively active and stimulate L-type calcium currents without agonist stimulation in isolated guinea pig and human cardiomyocytes. The authors also found that this effect was blocked by atenolol and propranolol.
Inverse agonism of 1 AR blockers has been extensively studied in rat and human myocardium. Most 1 AR blockers have shown a non-uniform inverse agonist action in human and rat myocardium exerting greater efficacy in the right atria than in other cardiac tissues [71] . Inverse agonism of 1 AR blockers has been described for their chronotropic and inotropic effect [70, 71] . Varma et al. [71] have investigated the inverse agonist properties of different 1 AR blockers in electrically-stimulated right atria, left ventricle and left ventricular papillary muscles finding that metoprolol exerts the greatest inverse agonist activity. Maak et al. [73] studied inverse agonist activity in human ventricular myocardium of different commonly used 1 AR blockers. The rank order of inverse agonist activity in this study was metoprolol > bisoprolol = nebivolol > carvedilol.
In addition, it is important to mention that inverse agonist properties of AR blockers could be altered in cardiovascular disease. Maack et al. [73, 74] have demonstrated that desensitization of cardiac 1 AR in heart failure could alter the inverse agonist activity of AR blockers and also established that 1 AR down-regulation may reduce inverse agonist response. In addition, we found that the inverse agonist activity of metoprolol is reduced by ageing, but not by the hypertensive stage induced by aortic coarctation [72] . More recently, metoprolol inverse agonist activity was found to be blunted in isolated atria of spontaneoulsy hypertensive rats [75] . Moreover, a significant correlation between the ventricular weight/body weight ratio and the inverse agonist potency of metoprolol was demonstrated, suggesting a possible link between cardiac hypertrophy and the reduction in the inverse agonist activity of metoprolol [75] . On the other hand, Janssens et al. [76] suggested that 1 AR in the anterior pituitary is positively coupled to AC but is constitutively active in a pertussis toxin-sensitive manner. These authors also suggested that CGP 20712A may act as an inverse agonist and 1 AR significantly contributes to basal AC activity in the pituitary.
Inverse agonistic properties of -blockers may be therapeutically relevant in clinical practice [67] . It is important to mention that excessive activation of cardiac AR, either in response to agonist stimulation or by constitutive activity, induces deleterious effects, including cardiac hypertrophy, myocyte apoptosis, fibroblast hyperplasia and arrhythmias [77] . It was demonstrated that inverse agonism at 2 AR could enhance coupling of this receptor to Gi-proteins, inhibiting hypertrophy and apoptosis of myocardial cells [78] . In addition, it was found that constitutive activity of AR results in pronounced agonist stimulation of these receptors [69, 79] . Therefore, inverse agonism at AR could have beneficial effects in the clinical use of -blockers.
In addition, excessive activation of cardiac AR induces desensitization and loss of function of these receptor subtypes agravating the loss of contractility of the failling heart. Therefore, restoration of 1 AR signaling is a therapeutic approach in the treatment of heart failure [80] . Considering that constitutive activity of GPCR induces receptor down--regulation [81] , it is expected that inverse agonists could exert a greater effect in receptor up-regulation with regards to neutral antagonists. It was found that 1 AR blockers with a high inverse agonist activity, such as bisoprolol and metoprolol [74] , induced an increase in AR density observed in human heart during long-term treatment with these 1 AR blockers [82] [83] [84] . Conversely, carvedilol has been found to exert only weak inverse agonism [85] , and it did not increase cardiac AR density in cardiac heart faillure.
It is well known that chronic use of long-acting 2 AR agonists increases asthma morbility and mortality due to receptor overactivation [86] . More recently, a possible therapeutic role of 2 AR inverse agonists in the treatment of asthma has been proposed. Preliminary studies have demonstrated that chronic treatment with 2 AR inverse agonists improves airway hyperresponsiveness to methacholine in a murine disease model [87] . On the other hand, Lin et al. [88] suggest that in the murine model of ashtma, several compensatory changes associated with either increased bronchodilator signaling or decreased bronchoconstrictive signaling result from the chronic administration of certain -blockers.
Taking together, inverse agonists seem to be useful in the treatment of chronic disease characterized by harmful effects resulting from 1 AR and 2 AR overactivation, such as heart failure and asthma, respectively.
-Adrenoceptors: The Low Affinity State
In the late nineties, the existence of a new putative 4 AR was described in tissues such as atria and brown adipocytes. In these works, different authors have found that (-)-CGP-12177 exerts activation of AR in the atria and adipocytes from 3 AR knockout mice [89, 90] . However, no gene was found that codes for the putative 4 AR, confirming that the putative 4 AR could be probably another binding site in the existing AR. In this way, some authors [91, 92] have demonstrated that the agonistic activity of CGP-12177 was dependent upon the presence of 1 AR, considering that 1 AR knockout abolished the cardiostimulation and the effects of CGP-12177 in brown adipose tissue.
Considering these findings, a new classification of AR binding site has emerged. 1 AR was described to have two binding sites: the high-affinity binding state and the lowaffinity state. The high-affinity state of 1 AR ( 1H ) is activatived and blocked by catecholamines, such as noradrenaline and adrenaline, and classical -blockers, such as carvedilol, metoprolol, bisoprolol and atenolol, respectively. Conversely, the low-affinity state ( 1L ) is activated with low potency by the atypical CGP-12177 and seems to be blocked by carvedilol and bupranolol [13] . Ligands of both 1H and 1L -adrenoceptors are summarized in Fig. (1) . Fig. (1) . Ligands to 1H -adrenoceptor and 1L -adrenoceptor binding sites.
In the last years, several studies have described the molecular mechanisms involved in the intracellular signaling of 1L -adrenoceptors. Pak and Fishman [93] have found that low concentration of CGP-12177 reduces AMPc accumulation induced by isoproterenol by preventing the binding of isoproterenol to the classical 1H -adrenoceptors. Conversely, high concentrations of CGP-12177 increases cAMP cytoplasmatic concentrations, suggesting that the 1L -affinity state also couples to stimulatory G protein as well as the 1H -adrenoceptor does.
Effects mediated through the low-affinity state of 1 AR have been studied mainly in in-vitro experiments. It is now clear that activation of 1L -adrenoceptors induces increase of sinoatrial beating [92, [94] [95] [96] , exerts a positive inotropic effects in the heart [89, [95] [96] [97] [98] , accelerates myocardial relaxation [99] [100] [101] , and induces atrial and ventricular arrhythmias [102, 103] .
Conversely, scarce studies have evaluated the properties of 1L -adrenoceptors ligands in vivo. Zakrzeska et al. [104] have studied the effects of CGP-12177 and cyanopindolol, two agonists at the 1L -adrenoceptors binding site, demonstrating that these agonists induce a positive inotropic and lusitropic effect in the pithed rat withouth effects on the vasculature.
Although nowadays there is no discussion regarding the existence of an additional binding site at the 1 AR, the physiological relevance of additional binding sites needs to be clarified. In this way, Mallem et al. [105] have found that activation of the low-affinity state of 1 AR in vascular smooth muscle induced vasodilatation in normotensive animals. Moreover, 1L -adrenoceptors induced relaxation was absent in spontaneously hypertensive rats, suggesting that down-regulation of this AR affinity state could be implicated in the increased vascular tone observed in hypertensive rats.
Considering the cardiac effect of 1L -adrenoceptors, activation of the low-affinity state of 1 AR could be deleterous in cardiovascular pharmacology. For instance, it was found that bucindolol, a non-specific -blocker with vasodilatadory properties, has no benefit on survival during treatment of heart failure, and this lack of effect might be related to its ability to activate 1L -adrenoceptors. Conversely, treatment with carvedilol, that actually blocks the low-affinity state of 1 AR, significantly reduces mortality in patients with different degrees of heart failure. However, further studies are needed to determine if blockade of the 1L -adrenoceptors contributes to the beneficial effect of carvedilol in heart failure [13] .
2-Adrenoceptors and the Agonist Trafficking
Nowadays it is accepted that GPCR can couple to more than one G protein, giving the possibility that different agonists can activate different signaling cascades [106] [107] [108] . This pharmacodynamic behaviour is actually called as agonist trafficking. Particularly for 2 AR, it is a well known fact that this subtype of AR can couple both to Gs and Gi-protein, inducing opposite effects on intracellular signaling [109] . In the heart, stimulation of Gs by means of 1 AR and 2 AR activation does not only enhance heart rate and contractility, but also induces deleterious cardiac effects through cardiomyocyte apoptosis [110] . Conversely, activation of Gi protein coupled to 2 AR could exert beneficial effects in patients with heart failure considering its antiapoptotic action [111] . However, an increased activation of Gi protein may also reduce the inotropic and chronotropic responsiveness induced by 1 AR Gs stimulation [8] . Coupling of cardiac 2 AR to Gi protein is increased in the failing heart by PKA phosphorilation of 2 AR [110] . The fact if uncoupling of 2 AR from Gs to Gi activation could play a cardioprotective role in patients with heart failure needs further investigation [8] .
Available 2 AR agonists differ in their ability to activate Gs or Gi protein coupled to 2 AR.Whilst terbutaline, zinterol, procaterol and salbutamol show a partial agonist response to the inotropic effect in ventricular cardiomyocytes from spontaneously hypertensive rats with heart failure, fenoterol exerts a total agonist response in these experiments [78] . Moreover, pretreatment with pertussis toxin, that inactivates Gi proteins, significantly enhances the contractile response to terbutaline, zinterol, procaterol and salbutamol treatment, withouth affecting fenoterol pharmacodynamics [78] . These results suggest that fenoterol might stimulate only the 2 AR-Gs protein pathway. It was found, in adult rat ventricular cardiomyocytes, that fenoterol activates selectively the Gs protein-pathway, whereas terbutaline and salbutamol stimulate the Gs-and Gi-protein pathways [112] .
So, it is possible to design 2 AR agonists with different pharmacological properties. Full agonists for the 2 AR-Gs protein pathway could improve bronchodilatation in the treatment of asthma. Conversely, full agonists for the 2 ARGi protein pathway may have a place in the treatment of heart failure, considering the antiapoptotic propertiers of this pathway.
-Adrenoceptors and the Oligomerization of Receptors
The fact that GPCR could undergo hetero-or homodimerization was first discovered in the early eighties [113] . Actually, it is well known that oligomerization of GPCR Carvedilol induces physical interactions resulting in significant changes in receptor pharmacology, ligand binding and signaling properties [114] [115] [116] .
Considering that 1 AR and 2 AR coexist in several tissues, the effect of oligomerization of these receptors has been studied in different tissues, especially in cardiomyocytes. Zhu et al. [8] were able to express either the mouse 1 AR or 2 AR, or both subtypes in cardiomyocytes from 1 AR and 2 AR double knockout mice. These authors have found that heterodimerization of 1 AR and 2 AR supressed the normally occurring constitutive ligand-independent activity of 2 AR. Conversely, intermolecular interaction between these subtypes of adrenoceptors enhances signaling efficiency of both AR subtypes optimizing the contractile response to AR agonists. Taking together, these results highlight the necessity to evaluate the effect of oligomerization of AR on receptor pharmacology in native cellular context rather than in naïve cell lines.
Heterodimerization of 2 AR with other GPCR subtypes was also evaluated in naïve HEK 293 cell line. In this context, it is important to mention that heterodimerization of 2 AR and 3 AR prevents coupling of these receptor subtypes to Gi proteins [117] . Moreover, angiotensin AT 1 -receptors and ARs also undergo heterodimerization in cardiac tissue [118] . Oligomerization of these receptors seems to have important pharmacological consequences, considering that treatment with a single antagonist, either at the AT 1 -receptor or the 1 AR, prevents the signaling induced by the activation of the second receptor.
Taking together, heterodimerization of AR with other adrenergic subtypes or other GPCR forms new entities with different pharmacological properties. Heterodimerization of AR seems to be therapeutically relevant for -blockers, considering that experimental evidence suggests that AR antagonists could also reduce signaling at AT 1 -receptor through a physical interaction between AR and AT 1 -receptor.
Polymorphisms of -Adrenoceptor
A polymorphism is a genetic variant that occurs in at least 1% of the population, which might be related or not to phenotypic differences in the gene product. The discovery of adrenoceptors polymorphic variants has recently leaded to the study of their impact on receptors function and their role in physiology, pathophysiology, and pharmacology.
The three subtypes of adrenoceptors ( 1 AR, 2 AR, and , all of them with polymorphic variants [119] .
-AR Polymorphisms
Polymorphic variants of the 1 AR have been extensively studied, in particular those related to cardiovascular function. In this line, variants located in the cytoplasmic tail portion of the 1 AR have been associated to cardiovascular phenotypic differences. Regarding the cytoplasmic tail, the most important polymorphism seems to be Arg 389 Gly, that was associated with altered basal receptor activity [120] . The Arg allele is considered the wild type, with a frecuence of 0.74 vs 0.26 in the Gly allele [120] . Arg 389 Gly polymorphism lies within the binding domain of 1 AR to Gs-protein, and therefore it is expected that single nucleotide mutations could affect constitutive activity and agonist efficacy [121] . Moreover, AR polymorphisms also modify efficacy of inverse agonists at 1 AR, affecting the therapeutic effects of these drugs. As an example, it has been observed that bucindolol exerts an inverse agonist action in ventricular trip extracted from cardiac patients homocygous for the Arg 389 allele, while the -blocker behaves as neutral antagonist in preparations from patients carrying the Gly 389 polymorphism [122] . Interestingly, in the BEST study, Arg 389 homozygous patients treated with bucindolol had fewer numbers of hospitalizations and a higher survival probability compared with Arg 389 homozygous patients treated with placebo, whereas Gly 389 carriers did not show improvement despite bucindolol treatment [126] . In another report [123] , it was shown that carvedilol induced a much stronger reduction in basal cAMP content in the Arg Another important polymorphism (located in a different area) is Ser 49 Gly. It has been demonstrated that the Gly 49 allele shows greater constitutive activity with regard to the wild type variant Ser 49 [120] because Gly 49 phenotype displays increased basal AC activity and an increased sensitivity to the inverse agonism of metoprolol [124] as well as greater desensitization and down-regulation when chronically stimulated. These characteristics seem to be important in heart failure treatment. In accordance, in experimental models, the down-regulation promoted by prolonged stimulation was greater for 49 Gly than for 49 Ser, reinforcing the idea that this can be a protective mechanism for patients with heart failure [125] . On the other hand, this polymorphism was associated with a lower mortality rate, considering that either homozygous or heterozygous for the Gly 49 variant showed a mortality rate of 23% at 5 years in comparison with the Ser 49 genotype with a mortality rate of 46% [126] .
Considering that in vitro studies have determined that the serine-to-glycine change at codon 49 increases agonistpromoted receptor down-regulation [127] , and that receptors containing Arg 389 have higher basal and isoproterenolstimulated receptor activities [120] , Shin and Johnson [128] have proposed that patients carrying Ser 49 and/or Arg 389 would have a better response to -blocker therapy. Supporting this hypothesis, Johnson et al. [129] reported that homozygosity for Arg 389 was significantly associated with greater diastolic blood pressure reduction with a stable dose of metoprolol in 40 patients with hypertension, despite there were no differences in the pharmacokinetic profile. In a similar manner, Bruck et al. [130] found an increased plasma renin activity response to a 1 AR agonist in Arg 389 allele carriers compared to Gly 389 , as well as a larger heart rate and contractility increases. Interestingly, the haplotype Ser 49 Arg 389 / Ser 49 Arg 389 had the greatest daytime reduction in diastolic blood pressure [129] .
According to Shin and Johnson [128] , data on the association between ADRB1 polymorphism and blood pressure response to a -blockers may also help to explain the under-lying physiological mechanism for the differences in blood pressure response to a -blockers between caucasians and african-americans, considering that compared with africanamericans, caucasians have a higher frequency of Arg 389 Arg genotype in the ADRB1 gene. Consequently, given that Arg 389 Arg has been identified as a predictor of good response to metoprolol, the genotype frequency difference between the two races may play a role in causing response differences to -blocker therapy [128] .
Of the twelve reported polymorphisms of 2 AR, only five predict aminoacid sequence changes: Gly 16 Arg, Gln 27 Glu, Val 34 Met, Thr 164 Ile, and Ser 220 Cys [119] . Although variations in ADRB2 have been associated with varying risks for obesity, diabetes mellitus, and essential hypertension, most of the studies have been carried out in order to determine their relation to reactive pulmonary disease [119] . In this way, it has been reported that the Gly 16 variant worsens respiratory function in asthmatic and cystic fibrosis patients [131, 132] . Considering that long-term treatment of asthmatic patients with 2 AR agonists evokes desensitization of both their bronchoprotective and bronchodilator effects, several studies have investigated the relationship between 2 AR polymorphisms and tolerance to agonist treatment [133] . It was found that patients homozygous for Gly 16 developed greater desensitization to long-term formoterol treatment [134] . However, several studies using short-acting or long-acting 2 AR agonists demonstrated that patients homozygous for Arg 16 or heterozygous Arg 16 Gly exhibited greater 2 AR tolerance than patients homozygous for Gly 16 [135] . To explain these findings, Liggett proposed a dynamic model of receptor regulation where endogenous catecholamines dynamically desensitize 2 AR in their basal state, and this occurs to a greater extent for Gly 16 than for Arg 16 polymorphism [136] . Hence, exogenous agonist induced desensitization should then be greater for Arg 16 than for Gly 16 (that already is endogenously desensitized) [133] .
In a longitudinal study designed to determine the relationship between 2 AR polymorphisms and weight gain and blood pressure elevation in obese patients, it was found that obese subjects carrying the Gly 16 allele of Arg 16 Gly polymporphism of the 2 AR gene had higher plasma leptin levels and leptin resistance, and greater increases in body weight and blood pressure along time [137] . This finding could be related to 2 AR downregulation associated to the Gly 16 allele [137] . These results are in accordance to those of Masuo et al. that reported an association between Gly 16 allele and increased insulin resistance, adiposity, and blood pressure accompanied by higher plasma noradrenaline levels in developing obesity [138] .
Regarding the relationship between 2 AR polymorphism and heart failure, it has been reported that the presence of the 164 Ile allele results in depressed myocardial contractile function in transgenic mice [139] . At the clinical setting, 1-year survival of patients with heart failure with the 164 Ile allele was 42% compared with 76% for patients with the wild-type 2 AR, suggesting that patients 164Ile allele and heart failure might be candidates for earlier aggressive intervention or cardiac transplantation [125, 140] .
AR Polymorphisms
Most of the studies of 3 AR polymorphisms were conducted in obese population. In 1995, a Trp 64 Arg polymorphism, located in the first intracellular loop of the receptor, was identified and reported to be associated with accelerated weight gain, insulin resistance and early onset of diabetes mellitus [141] . Later, it was reported that the Arg 64 variant causes blunted receptor responsiveness to 3 AR agonist [142] , and other authors found that the Trp 64 Arg mutation is associated with a lower basal metabolic rate in different populations, suggesting that subjects with the Trp 64 Arg mutation might have defects in the 3 AR-mediated thermogenic response to sympathetic stimulation [141] .
Given the fact that pregnancy can be assumed as a physiological state of insulin resistance, Festa et al. [143] studied the relationship between the Arg 64 allele and glucose tolerance during pregnancy. In 179 pregnant women, the authors found that in women with mild gestational diabetes, the Trp 64 Arg polymorphism was more frequent than in women with normal glucose tolerance. Furthermore, the Trp 64 Arg polymorphism was associated with increased weight gain during pregnancy and increased postload glucose, insulin, and C peptide values during the oral glucose tolerance test [143] . In addition, in a recent meta-analysis, Siyan and Ho revealed a small but significant association of the Trp 64 Arg polymorphism with insulin resistance in Asian population [144] . On the other hand, aside from insulin resistance, the Arg 64 allele may affect insulin secretion [144] . In a prospective study, Walson et al. [145] suggested that subjects carrying the Arg 64 allele have decreased acute insulin release but no increased insulin resistance (using insulin sensitivity as index) in a young and lean cohort. Furthermore, a dizygotic twin study found that the adrenergic 3 AR might be involved in the regulation of insulin secretion, and individuals with Trp64Arg mutation presented an impaired insulin secretion.
It was found that the Trp 64 Arg polymorphism is related to increased sensitivity to the pressure effects of noradrenaline [146] and, interestingly, Hawaguchi et al. [137] determined that this polymorphism is associated to future weight gain, blood pressure elevation, and weight gain-induced blood pressure elevation, and proposed that blunted 3 AR function and resultant lower metabolic rates through sympathetic nerve activity producing future weight gain and increased sensitivity to pressure effects of norepinephrine could be responsible of blood pressure elevation in obese subjects.
CONCLUSION
In the last decades new AR pharmacodynamic properties have been discovered that could greatly impact in the clinical use of -adrenergic agents. Concepts such as multiple binding sites, constitutive activity, polymorphism and intracellular signaling may contribute in the discovery of more efficacious drugs for heart failure and asthma treatments. Additionally, genotypic characterization of patients could improve selection of patients during -adrenergic pharmacotherapies (Figs. 2 and 3) .
AR shows relatively high constitutive activity in both cardiac and pulmonar tissues. Most -blockers exert an inverse agonism that could contribute to beneficial effects in the heart failure treatment (Fig. 2) . However, further research is needed to establish the real impact of -blocker inverse agonism in cardiac failure treatment, considering that some agents have additional pharmacodynamic properties.
More recently, a possible role of 2 AR inverse agonists, such as nadolol, in the chronic treatment of asthma has been suggested (Fig. 3) . The FDA has allowed the performance of a clinical trial to evaluate the nadolol efficacy in chronic treatment of mild asthma [147] . Preliminary results from this study support findings observed in preclinical studies considering that nadolol chronic treated asthmatic patients showed an attenuated hyperresponsiveness to methacholine [148] .
Although nowadays there is consensus regarding the existence of 1 AR additional binding site, their physiological relevance needs to be clarified. It was proposed thatblockers with agonist properties at the 1L -adrenoceptors binding site may exert neutral or harmful effects when used in the treatment of heart failure (Fig. 2) . Activation of the low-affinity state of 1 AR could be deleterous in cardiovascular pharmacology.
Because the ability of 2 AR to couple to Gs or Gi-protein and activate different signaling cascades (Gs, Gi or both Gproteins), a new classification of actually and developmental 2 AR agonist is needed. Full agonists for the 2 AR-Gs protein pathway would be useful for improving bronchodilatation in the acute treatment of asthma. Conversely, considering the antiapoptotic properties of full agonists for the 2 AR-Gi protein pathway, these compounds may have a place in heart failure managment (Fig. 3) .
Polymorphic variants of different AR subtypes have an impact in the understanding of physiology and pathophysiology. The findings regarding their role in chronic diseases prognosis and evolution, and in pharmacological response to -blockers and -agonists, open the possibility that patient selection for a treatment might be based on genetic variances in a near future (Figs. 2 and 3) .
Finally, the complexity of ARs function markedly increased in the last decades but, considering the appearance of new pharmacological paradigms and their relevance to public health, more studies will be needed in order to be able to apply novel concepts to the clinical practice. 
